Medicine
Retrovir 200 mg/20 mL injection
Retrovir 200 mg/20 mL injection is a prescription medicine containing Zidovudine for intravenous use, marketed by ViiV Healthcare, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 15° to 25°C (59° to 77°F) and protect from moisture. Store at 15° to…
Key facts
- Active ingredient (INN)
- Zidovudine
- Brand
- Retrovir
- Strength
- 200 mg/20 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 5 vials of 20 mL
- Marketing authorisation holder
- ViiV Healthcare
- Manufacturer
- ViiV Healthcare
- Origin register
- US FDA, United States
- Storage
- Store at 15° to 25°C (59° to 77°F) and protect from moisture. Store at 15° to 25°C (59° to 77°F). Store vials at 15° to 25°C (59° to 77°F) and protect from light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J05AF01 Zidovudine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 4 November 2010
- Identifiers
- RxCUI 108396, 198352, 201907 +3DailyMed set ID 6df09f15-b102-431c-adde-d7aeef6f5d84NDC 49702-213Application NDA019951
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 5 vial, single-use in 1 carton / 20 mL in 1 vial, single-use | 49702-213-26 | ViiV Healthcare | 1 December 2016 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 19 March 1987 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Zidovudine
Clinical summary
Zidovudine is a human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor indicated for treatment of Human Immunodeficiency Virus (HIV-1) infection in combination with other antiretroviral agents, among other approved uses. MedsAcross supplies Zidovudine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ZidovudineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- RETROVIR prescribing information (ViiV Healthcare) · U.S. National Library of Medicine, DailyMed
Need Retrovir 200 mg/20 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.